Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis

By Moses Harold   Brandes David W.  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2679-2690

Informa Healthcare

Access to resources Recommend Favorite

Satisfaction with participation in multiple sclerosis and spinal cord injury

By Yorkston Kathryn M.   Bamer Alyssa   Johnson Kurt   Amtmann Dagmar  

Disability and Rehabilitation, Vol. 34, Iss. 9, 2012-05 ,pp. : 747-753

Informa Healthcare

Access to resources Recommend Favorite

Multiple Sclerosis: Association to HLA DQα in a Tropical Population

By  

Experimental and Clinical Immunogenetics, Vol. 16, Iss. 3, 1999-06 ,pp. : 131-138

Karger

Access to resources Recommend Favorite

Reliability, validity, and applicability of the Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) for adults with multiple sclerosis

By Demers L.   Monette M.   Lapierre Y.   Arnold D. L.   Wolfson C.  

Disability and Rehabilitation, Vol. 24, Iss. 1-3, 2002-01 ,pp. : 21-30

Informa Healthcare

Access to resources Recommend Favorite

Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs*

By Birnbaum Howard G.   Ivanova Jasmina I.   Samuels Seth   Davis Matthew   Cremieux Pierre Y.   Phillips Amy L.   Meletiche Dennis  

Current Medical Research and Opinion, Vol. 25, Iss. 4, 2009-04 ,pp. : 869-877

Informa Healthcare

Access to resources Recommend Favorite